Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

Cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) is being evaluated in the Phase II ALPHA3 trial in patients who respond to first-line chemoimmunotherapy but remain positive for minimal residual disease. At day 45, plasma circulating tumour DNA had decreased by a median of 97.7 per cent with cema-cel, versus a 26.6 per cent increase under observation. No cytokine release syndrome, neurotoxicity, graft-versus-host disease or treatment-related serious adverse events were reported at the interim cut-off.

Cema-cel is edited with TALEN rather than CRISPR-Cas. Pairs of TALEN proteins recognise selected DNA sequences and bring together FokI nuclease domains, which cut the intervening DNA. Error-prone repair then disrupts TRAC, removing the donor cells’ native T-cell receptor to reduce graft-versus-host disease, and CD52, originally intended to protect the cells during anti-CD52 lymphodepletion. A lentiviral vector separately introduces the CD19-directed CAR.

The analysis remains small and interim; MRD clearance has not yet demonstrated improved event-free survival. RMAT and Fast Track designations facilitate regulatory interaction but do not constitute approval.

The news was revealed in a press release issued by Allogene Therapeutics on 29 July 2026. The TALEN construction was published in Molecular Therapy on 14 December 2022.